FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2200883957> ?p ?o ?g. }

• W2200883957 endingPage "2784" @default.
• W2200883957 startingPage "2780" @default.
• W2200883957 abstract "Abstract Fifty-one children between 26 and 214 months of age (median, 100 months) with acute lymphoblastic leukemia (ALL) were grafted in second remission from HLA-identical sibling donors (except for two patients who were grafted with a marrow with 1 antigen-mismatch). Initial treatment and relapse therapy were similar in all patients according to the BFM- and CoALL-protocols (front line: 38 patients according to BFM- protocols and 13 patients according to CoALL-protocols; relapse: 12 patients in study ALL-REZ-BFM 83, 17 in ALL-REZ-BFM 85, 20 in ALL-REZ- BFM 87, and two in ALL-REZ-BFM 90). The conditioning regimens were different, consisting of cyclophosphamide (CY) total body irradiation (TBI) plus (n = 27), VP-16-TBI (n = 23), and CY-TBI and ARA-C (n = 1). Three patients had a second graft after conditioning with CY-TBI for the first transplantation. The second ablative regimen consisted of CY plus VP-16 in the first patient and CY plus busulfan in the two other patients, one of whom relapsed again. All patients but three had bone marrow (BM), either isolated or combined, relapses. Twenty-nine of the patients are in continuous complete remission (CCR), ranging from 1 to 67 months after transplantation with a median time of 30 months. One patient was lost to follow-up in continuous remission. Nine patients died from treatment-related complications (infections and graft-versus- host disease) and 12 patients suffered a leukemic relapse; three of them received a second graft and two are in CCR. Kaplan-Meier analysis yields an event-free survival (EFS) of 0.52 +/- 0.08. The probability of a 7-year relapse-free interval (RFI) is 0.68 +/- 0.08. EFS for patients with late relapses is 0.47 +/- 0.12 and for patients with early relapses 0.56 +/- 0.1. The RFI for patients with late relapses is 0.65 +/- 0.12 and for patients with early relapses 0.69 +/- 0.11. There is a nonsignificant trend towards superior results for patients grafted after conditioning with VP-16 plus TBI. When all patients who are not in CCR at day +125 (which is the median interval between relapse diagnosis and BM transplantation [BMT]) are excluded from the chemotherapy results, there is no significant difference between the results of BMT and chemotherapy for late relapses. On the other hand, there is a significant advantage between chemotherapy and BMT for early relapses over chemotherapy (P less than or equal to .01)." @default.
• W2200883957 created "2016-06-24" @default.
• W2200883957 creator A5012680652 @default.
• W2200883957 creator A5014093899 @default.
• W2200883957 creator A5015116246 @default.
• W2200883957 creator A5016105550 @default.
• W2200883957 creator A5017002895 @default.
• W2200883957 creator A5040186476 @default.
• W2200883957 creator A5058595867 @default.
• W2200883957 creator A5062024144 @default.
• W2200883957 creator A5072991370 @default.
• W2200883957 creator A5073379037 @default.
• W2200883957 date "1991-11-15" @default.
• W2200883957 modified "2023-10-02" @default.
• W2200883957 title "Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study" @default.
• W2200883957 cites W1598597181 @default.
• W2200883957 cites W1856021884 @default.
• W2200883957 cites W2003778995 @default.
• W2200883957 cites W2042226495 @default.
• W2200883957 cites W2044149267 @default.
• W2200883957 cites W2051703407 @default.
• W2200883957 cites W2180207100 @default.
• W2200883957 cites W2322358118 @default.
• W2200883957 cites W2330491673 @default.
• W2200883957 cites W2339110381 @default.
• W2200883957 cites W2410117880 @default.
• W2200883957 cites W2411815867 @default.
• W2200883957 cites W2415619833 @default.
• W2200883957 cites W3112116562 @default.
• W2200883957 doi "https://doi.org/10.1182/blood.v78.10.2780.2780" @default.
• W2200883957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1824271" @default.
• W2200883957 hasPublicationYear "1991" @default.
• W2200883957 type Work @default.
• W2200883957 sameAs 2200883957 @default.
• W2200883957 citedByCount "164" @default.
• W2200883957 countsByYear W22008839572012 @default.
• W2200883957 countsByYear W22008839572013 @default.
• W2200883957 countsByYear W22008839572014 @default.
• W2200883957 countsByYear W22008839572015 @default.
• W2200883957 countsByYear W22008839572016 @default.
• W2200883957 countsByYear W22008839572017 @default.
• W2200883957 countsByYear W22008839572018 @default.
• W2200883957 countsByYear W22008839572020 @default.
• W2200883957 countsByYear W22008839572021 @default.
• W2200883957 countsByYear W22008839572022 @default.
• W2200883957 crossrefType "journal-article" @default.
• W2200883957 hasAuthorship W2200883957A5012680652 @default.
• W2200883957 hasAuthorship W2200883957A5014093899 @default.
• W2200883957 hasAuthorship W2200883957A5015116246 @default.
• W2200883957 hasAuthorship W2200883957A5016105550 @default.
• W2200883957 hasAuthorship W2200883957A5017002895 @default.
• W2200883957 hasAuthorship W2200883957A5040186476 @default.
• W2200883957 hasAuthorship W2200883957A5058595867 @default.
• W2200883957 hasAuthorship W2200883957A5062024144 @default.
• W2200883957 hasAuthorship W2200883957A5072991370 @default.
• W2200883957 hasAuthorship W2200883957A5073379037 @default.
• W2200883957 hasBestOaLocation W22008839571 @default.
• W2200883957 hasConcept C126322002 @default.
• W2200883957 hasConcept C141071460 @default.
• W2200883957 hasConcept C2776694085 @default.
• W2200883957 hasConcept C2776755627 @default.
• W2200883957 hasConcept C2778461978 @default.
• W2200883957 hasConcept C2778880498 @default.
• W2200883957 hasConcept C2779263901 @default.
• W2200883957 hasConcept C2780007613 @default.
• W2200883957 hasConcept C2780611847 @default.
• W2200883957 hasConcept C2781107101 @default.
• W2200883957 hasConcept C2909962599 @default.
• W2200883957 hasConcept C2911091166 @default.
• W2200883957 hasConcept C71924100 @default.
• W2200883957 hasConcept C90924648 @default.
• W2200883957 hasConceptScore W2200883957C126322002 @default.
• W2200883957 hasConceptScore W2200883957C141071460 @default.
• W2200883957 hasConceptScore W2200883957C2776694085 @default.
• W2200883957 hasConceptScore W2200883957C2776755627 @default.
• W2200883957 hasConceptScore W2200883957C2778461978 @default.
• W2200883957 hasConceptScore W2200883957C2778880498 @default.
• W2200883957 hasConceptScore W2200883957C2779263901 @default.
• W2200883957 hasConceptScore W2200883957C2780007613 @default.
• W2200883957 hasConceptScore W2200883957C2780611847 @default.
• W2200883957 hasConceptScore W2200883957C2781107101 @default.
• W2200883957 hasConceptScore W2200883957C2909962599 @default.
• W2200883957 hasConceptScore W2200883957C2911091166 @default.
• W2200883957 hasConceptScore W2200883957C71924100 @default.
• W2200883957 hasConceptScore W2200883957C90924648 @default.
• W2200883957 hasIssue "10" @default.
• W2200883957 hasLocation W22008839571 @default.
• W2200883957 hasOpenAccess W2200883957 @default.
• W2200883957 hasPrimaryLocation W22008839571 @default.
• W2200883957 hasRelatedWork W1993231178 @default.
• W2200883957 hasRelatedWork W2049808065 @default.
• W2200883957 hasRelatedWork W2252635646 @default.
• W2200883957 hasRelatedWork W2339482838 @default.
• W2200883957 hasRelatedWork W2398620837 @default.
• W2200883957 hasRelatedWork W2412093160 @default.
• W2200883957 hasRelatedWork W2615902868 @default.
• W2200883957 hasRelatedWork W2889442370 @default.
• W2200883957 hasRelatedWork W2979908979 @default.

• next